Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Artemether

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Artemether
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Artemisinin and derivatives, plain
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BE02; WHO ATC P01BE05

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Artemether, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Artemether in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Artemether with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

    NCT05842954 · start 2024-03-07

    Registered record
    Registry ID
    NCT05842954
    Conditions
    Uncomplicated Plasmodium Falciparum Malaria
    Interventions
    KLU156; Coartem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-03-07
    Completion
    2025-11-25
    Enrolment
    1,720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Plasmodium Falciparum Malaria
    InterventionKLU156; Coartem
    PhasePhase 3
    Registry statusCompleted

  • Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

    NCT05750628 · start 2024-01-23

    Registered record
    Registry ID
    NCT05750628
    Conditions
    Uncomplicated Plasmodium Falciparum Malaria
    Interventions
    INE963; KAE609 (Cipargamin); SoC (Coartem); KLU156
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-23
    Completion
    2026-06-23
    Enrolment
    327

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Plasmodium Falciparum Malaria
    InterventionINE963; KAE609 (Cipargamin); SoC (Coartem); KLU156
    PhasePhase 2
    Registry statusRecruiting

  • Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics

    NCT05757167 · start 2023-11-06

    Registered record
    Registry ID
    NCT05757167
    Conditions
    Malaria,Falciparum; Malaria in Pregnancy; Malaria in Childbirth; Pregnancy; Neonatal Health; Low Birthweight; Stillbirth; Gestational Age and Weight Conditions; Preterm Birth
    Interventions
    Malaria High-Sensitivity Rapid Diagnostic Test (HS-RDT); Artemether-lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-11-06
    Completion
    2026-12
    Enrolment
    2,174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum; Malaria in Pregnancy; Malaria in Childbirth; Pregnancy +5 more
    InterventionMalaria High-Sensitivity Rapid Diagnostic Test (HS-RDT); Artemether-lumefantrine (AL)
    PhasePhase 4
    Registry statusActive not recruiting

  • CHILD (Child Health and Infection With Low Density) Malaria

    NCT05567016 · start 2023-07-18

    Registered record
    Registry ID
    NCT05567016
    Conditions
    Malaria,Falciparum; Malaria
    Interventions
    Active case detection using molecular testing (ACDm); Passive case detection using molecular testing (PCDm); Control (standard of care)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-07-18
    Completion
    2025-11-28
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum; Malaria
    InterventionActive case detection using molecular testing (ACDm); Passive case detection using molecular testing (PCDm); Control (standard of care)
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics of Antimalarials in Breastfeeding Ugandan Mother-infant Pairs

    NCT05676645 · start 2023-03-20

    Registered record
    Registry ID
    NCT05676645
    Conditions
    Malaria,Falciparum
    Interventions
    Artemether-lumefantrine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-03-20
    Completion
    2026-12-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum
    InterventionArtemether-lumefantrine
    PhaseNot recorded
    Registry statusActive not recruiting

  • Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield

    NCT05540470 · start 2022-09-12

    Registered record
    Registry ID
    NCT05540470
    Conditions
    Malaria, Vivax
    Interventions
    PART; Malakit; CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS; QUALITATIVE STUDY
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-09-12
    Completion
    2025-04-25
    Enrolment
    1,991

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Vivax
    InterventionPART; Malakit; CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS; QUALITATIVE STUDY
    PhaseNot applicable
    Registry statusCompleted

  • Controlled Human Malaria Infection Transmission Model - Phase A

    NCT04280692 · start 2022-08-22

    Registered record
    Registry ID
    NCT04280692
    Conditions
    Malaria,Falciparum
    Interventions
    PfSPZ Challenge; Sulfadoxine-Pyrimethamine; Piperaquine; Artemether lumefantrine; Primaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Suspended
    Start
    2022-08-22
    Completion
    2026-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum
    InterventionPfSPZ Challenge; Sulfadoxine-Pyrimethamine; Piperaquine; Artemether lumefantrine +1 more
    PhasePhase 1 / Phase 2
    Registry statusSuspended

  • Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia

    NCT06300970 · start 2022-08-09

    Registered record
    Registry ID
    NCT06300970
    Conditions
    Plasmodium Falciparum; Malaria; Uncomplicated Malaria
    Interventions
    Amodiaquine-artesunate (ASAQ); Artemether+Lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-09
    Completion
    2023-08-16
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum; Malaria; Uncomplicated Malaria
    InterventionAmodiaquine-artesunate (ASAQ); Artemether+Lumefantrine (AL)
    PhasePhase 4
    Registry statusCompleted

  • Blood-Stage Plasmodium Vivax Cell Bank

    NCT05095272 · start 2022-02-15

    Registered record
    Registry ID
    NCT05095272
    Conditions
    Malaria
    Interventions
    HMPBS02-Pv
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-02-15
    Completion
    2022-09-15
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionHMPBS02-Pv
    PhasePhase 1
    Registry statusCompleted

  • Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women

    NCT07358767 · start 2021-07-01

    Registered record
    Registry ID
    NCT07358767
    Conditions
    Malaria
    Interventions
    Artemether-lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-07-01
    Completion
    2023-03-31
    Enrolment
    3,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtemether-lumefantrine (AL)
    PhaseNot applicable
    Registry statusCompleted

  • A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)

    NCT03939104 · start 2021-06-30

    Registered record
    Registry ID
    NCT03939104
    Conditions
    Plasmodium Falciparum Malaria (Uncomplicated)
    Interventions
    Artemether-lumefantrine+amodiaquine; Artemether-lumefantrine+placebo; Artesunate-mefloquine+piperaquine; Artesunate-mefloquine+placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-30
    Completion
    2023-01-28
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria (Uncomplicated)
    InterventionArtemether-lumefantrine+amodiaquine; Artemether-lumefantrine+placebo; Artesunate-mefloquine+piperaquine; Artesunate-mefloquine+placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria

    NCT04546633 · start 2021-02-16

    Registered record
    Registry ID
    NCT04546633
    Conditions
    Uncomplicated Plasmodium Falciparum Malaria
    Interventions
    KAF156; LUM-SDF; Coartem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-02-16
    Completion
    2024-08-28
    Enrolment
    295

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Plasmodium Falciparum Malaria
    InterventionKAF156; LUM-SDF; Coartem
    PhasePhase 2
    Registry statusCompleted

  • A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.

    NCT03923725 · start 2020-09-01

    Registered record
    Registry ID
    NCT03923725
    Conditions
    Plasmodium Falciparum Malaria (Uncomplicated)
    Interventions
    Artemether-lumefantrine+ Amodiaquine (AL+AQ); Artemether-lumefantrine + placebo (AL+PBO); Artesunate-mefloquine+piperaquine (AS-MQ+PPQ); Artesunate-mefloquine+placebo (AS-MQ+PBO)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-01
    Completion
    2024-03-15
    Enrolment
    2,583

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria (Uncomplicated)
    InterventionArtemether-lumefantrine+ Amodiaquine (AL+AQ); Artemether-lumefantrine + placebo (AL+PBO); Artesunate-mefloquine+piperaquine (AS-MQ+PPQ); Artesunate-mefloquine+placebo (AS-MQ+PBO)
    PhasePhase 3
    Registry statusCompleted

  • Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya

    NCT07362498 · start 2020-06-01

    Registered record
    Registry ID
    NCT07362498
    Conditions
    Malaria Falciparum
    Interventions
    Artemether + Lumefantrine; Dihydroartemisin-piperaquine; Artesunate-Amodiaquine (AS-AQ); Pyronaridine - artesunate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-06-01
    Completion
    2024-01-31
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Falciparum
    InterventionArtemether + Lumefantrine; Dihydroartemisin-piperaquine; Artesunate-Amodiaquine (AS-AQ); Pyronaridine - artesunate
    PhaseNot recorded
    Registry statusCompleted

  • Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites

    NCT04310085 · start 2020-02-19

    Registered record
    Registry ID
    NCT04310085
    Conditions
    Malaria,Falciparum; Parasitemia; Protozoan Infections; Parasitic Disease
    Interventions
    Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet; PfSPZ-DVI Challenge
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-19
    Completion
    2020-12-17
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum; Parasitemia; Protozoan Infections; Parasitic Disease
    InterventionArtemether-Lumefantrine 20 Mg-120 Mg Oral Tablet; PfSPZ-DVI Challenge
    PhasePhase 1
    Registry statusCompleted